Overview: DMD BMD Mutation TestIntroduction: The DMD BMD Mutation Test detects mutations in DMD/BMD genes to diagnose muscular dystrophy, causing muscle weakness or mobility issues. Aligned with 2023 MDA guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected muscular dystrophy.
Other Names: Duchenne/Becker Muscular Dystrophy Test, DMD Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: DMD/BMD genetic testing began in the 1980s with dystrophin gene discovery. PCR-based mutation detection emerged in the 1990s, and by the 2000s, expanded panels improved accuracy.
Purpose: Diagnoses Duchenne or Becker muscular dystrophy, guides treatment, and monitors genetic mutations in patients with muscle weakness or mobility issues.
Test Parameters: 1. DMD/BMD Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like muscle weakness or mobility issues, and list family history of muscular dystrophy.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, mobility issues, or family history of muscular dystrophy. Include current medications or prior genetic testing results.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for genetic counseling or therapy.
Procedural Considerations: Uses PCR to detect DMD/BMD gene mutations (e.g., deletions, duplications). Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Contamination or low DNA yield can affect results. Rare mutations may require additional testing.
Clinical Significance: Positive mutation results confirm DMD/BMD, prompting treatment or genetic counseling. Negative results may require further genetic testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation.
Additional Supporting Tests: Muscle biopsy, creatine kinase levels, or EMG to confirm muscular dystrophy.
Test Limitations: False negatives may occur with rare mutations. Results require clinical correlation.
References: MDA Muscular Dystrophy Guidelines, 2023; Neuromuscular Disorders, Mercuri E, 2022.
